Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 14/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.83 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.83 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.83 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.83 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.83 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21093918 | 1.00 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21050368 | 1.00 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21050366 | 1.00 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22915503 | 0.95 | APP (0.91) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21050352 | 0.91 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21093525 | 0.91 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21050354 | 0.91 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21050353 | 0.91 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21050460 | 0.90 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21050464 | 0.90 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484884-B1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | claimed |
| US-10730881-B2 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2020-08-04 | — | — | US | claimed |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-13 | — | — | US | claimed |
| EP-3484884-B1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10730881-B2 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730881-B2 | Fused pyrimidine derivatives | APP, UPF1, PSEN1 | APP 1/4885PSEN1 3/4885PSEN2 10/4885 |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | APP, UPF1, PSEN1 | APP 1/4885PSEN1 3/4885PSEN2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.